Sabatolimab in addition to azacitidine for myelodysplastic syndromes – first-line

Sabatolimab in addition to azacitidine is in clinical development for the treatment of higher risk myelodysplastic syndromes (MDS) in adults. Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. MDS are long-term debilitating and life-threatening diseases
Sabatolimab targets an inhibitory receptor that regulates adaptive and innate immune responses. Azacitidine is already approved for MDS and the addition of sabatolimab may provide synergistic efficacy and safety. If licensed, sabatolimab in addition to azacitidine will offer an additional treatment option for patients with untreated higher risk who currently have few well-tolerated effective therapies available.